text: Yo, check it out, let me break it down for you,
  We got N-methyl-D-aspartate, NMDA, and that's true,
  Plus (+/-)2-amino-5-phosphonovalerate, 2AP5, in the mix,
  And let's not forget about (+/-)cis-2.3-piperidine dicarboxylate, cis-PDA, it's the fix.
  
  We're diving into the neonatal rat spinal cord in vitro,
  Quantitatively examining these interactions, let's go,
  NMDA and cis-PDA causing motoneuronal depolarizations,
  Concentration-dependent, they got the power, no hesitations.
  
  The response from cis-PDA, about 60% of NMDA's might,
  When combined with fixed cis-PDA concentrations, it's outta sight,
  NMDA comes through, depolarizations on top of cis-PDA's base,
  Dose-response curve intersecting, moving to the right, setting the pace.
  
  2AP5 steps in, shifting NMDA's curve to the side,
  Schild regression analysis with a pKB of 5.0, we ride,
  2AP5 also moves the cis-PDA curve, no doubt,
  Apparent KB 3.1 X 10(-5) M, shifting about.
  
  Cis-PDA's contribution to the NMDA + cis-DPA curve, erased,
  2AP5 be doing work, no component of cis-PDA left to be traced,
  These results align with drug-receptor theory, it's true,
  Full agonist NMDA, competitive antagonist 2AP5, and partial agonist cis-PDA, that's the crew.
  
  Excitatory amino acid receptors in the mix, that's the key,
  NMDA, selective agonist, that's how it's meant to be,
  So there you have it, the science and the theory laid out,
  In the style of rap, we break it down, no doubt.